Review for 'A 52‐week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N‐ISM study'

Subjects :: medicine.medical_specialty
business.industry
Type 2 diabetes
medicine.disease
law.invention
Metformin
chemistry.chemical_compound
Ipragliflozin
Randomized controlled trial
chemistry
law
Sitagliptin
Internal medicine
medicine
business
medicine.drug

Tools